COMPOUNDS / NOOTROPIC / BROMANTANE
NOOTROPIC

BROMANTANE

MEDIUM RISK
BEST FOR:Cognition●●●●●●●○○○7/10
BROMANTANE · LADASTEN · BM-050 · BROMANTAN · 2-BROMO-Α-ERGOLANE
NootropicAdaptogenActoprotectorSoviet / RussianDopamineWADA-banned

A synthetic adaptogen and actoprotector that enhances dopamine synthesis and physical endurance without typical stimulant dependence.

ROUTE / DOSAGE
LOW10-50mg
STANDARD50-100mg
HIGH100-200mg
Note: Take in morning; effects on dopamine synthesis are cumulative over days
CYCLE
Daily use acceptable up to 2 months no tolerance observed in studies
BIOAVAILABILITY
~42% oral
ACTIVE DURATION
8-12h (subjective)
STORAGE
Room temperature dry away from light
HALF-LIFE
7-11h (plasma)
DURATION BREAKDOWN
Total8-12h
Onset30-60min
Come up1-2h
Peak2-3h
Offset3-5h
After effects6-12h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
8 documented
Increased physical endurance and work capacity
Mild central stimulation without euphoria
Thermoprotection against heat stress
Enhanced dopamine-mediated alertness
Reduced fatigue during prolonged exertion
Mydriasis
Slight decrease in body temperature
Improved recovery after extreme physical loads
§ 02 — RISKS
Neurotoxicity at high doses including behavioral suppression and cholinergic disruption
Temperature dysregulation — hypothermia initially, potential hyperthermia with prolonged use
Gastrointestinal effects (regurgitation, diarrhea, polyuria) at toxic doses
Sex-dependent psychodysleptic effects at high doses
Blepharoptosis and Kussmaul-like respiration at extreme doses (>5-10 g/kg)
Reduced pain sensitivity threshold at moderate-to-high doses
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Animal studies show bromantane improves physical work capacity by 1.3-1.6 times compared to amphetamine at optimal doses, with effects lasting at least 24 hours. EEG studies in rats reveal a two-phase stimulant profile with peaks at 2-3 and 6-7 hours, persisting up to 8 hours. A two-month oral administration study found no development of tolerance or drug dependence, though sex-dependent psychodysleptic effects were observed at toxic doses (600 mg/kg). Thermoprotective effects during overheating have been documented, alongside alterations in protein metabolism and antioxidant systems. However, the evidence base is predominantly Russian-language animal research with very limited human clinical trial data.

§ 06 — SOURCES
[1]
Plant Adaptogens-History and Future Perspectives (PMID 34445021)
pubmed.ncbi.nlm.nih.gov ↗
[2]
Toxic effect of single treatment with bromantane on neurological status (PMID 12124651)
pubmed.ncbi.nlm.nih.gov ↗
[3]
Study of heat-protective effects of bromantane (PMID 7793100)
pubmed.ncbi.nlm.nih.gov ↗
[4]
An acute toxicity study of bromantane (PMID 10763112)
pubmed.ncbi.nlm.nih.gov ↗
[5]
Effect of bromantane on physical work capacity of laboratory animals (PMID 9929819)
pubmed.ncbi.nlm.nih.gov ↗
[6]
Quantitative pharmaco-EEG analysis of bromantane action (PMID 8312546)
pubmed.ncbi.nlm.nih.gov ↗
[7]
Effect of bromantane on rat neurologic status in two month course (PMID 11109517)
pubmed.ncbi.nlm.nih.gov ↗
[8]
PsychonautWiki - Bromantane
psychonautwiki.org ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT